This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Andrew A. F. Hack net worth and biography

Andrew Hack Biography and Net Worth

Director of Dynavax Technologies

Dr. Hack has been a member of the Dynavax board since August 2019 and became interim Chairman of the Board in May 2020. Dr. Hack is a Managing Director at Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Dr. Hack served as Chief Financial Officer of Editas Medicine, Inc. (NASDAQ: EDIT), from July 2015 to March 2019. Prior to joining Editas, he was a portfolio manager at Millennium Management LLC, an institutional asset manager, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Dr. Hack was a healthcare analyst at HealthCor Management, L.P., a registered investment advisor. Previously, he served as a healthcare analyst for hedge fund Carlyle-Blue Wave Partners and as principal of the MPM BioEquities Fund, a hedge fund that was affiliated with MPM Capital. Earlier in his career, Dr. Hack was Director of Life Sciences and co-founder of Reify Corporation, a life science tools and drug discovery company. Dr. Hack serves as a director of Allena Pharmaceuticals, Inc. and Mersana Therapeutics, Inc. He received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.

What is Andrew A. F. Hack's net worth?: The estimated net worth of Andrew A. F. Hack is at least $32.83 million as of March 27th, 2024. Dr. Hack owns 2,697,267 shares of Dynavax Technologies stock worth more than $32,825,739 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Hack may own. Learn More about Andrew A. F. Hack's net worth.
How do I contact Andrew A. F. Hack?: The corporate mailing address for Dr. Hack and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]. Learn More on Andrew A. F. Hack's contact information.
Has Andrew A. F. Hack been buying or selling shares of Dynavax Technologies?: Andrew A. F. Hack has not been actively trading shares of Dynavax Technologies over the course of the past ninety days. Most recently, Andrew A. F. Hack sold 1,500,000 shares of the business's stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $14.39, for a transaction totalling $21,585,000.00. Following the completion of the sale, the director now directly owns 915,000 shares of the company's stock, valued at $13,166,850. Learn More on Andrew A. F. Hack's trading history.
Who are Dynavax Technologies' active insiders?: Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.
Are insiders buying or selling shares of Dynavax Technologies?: In the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 54,641 shares worth more than $729,199.23. The most recent insider tranaction occured on May, 31st when Director Francis Cano sold 3,615 shares worth more than $43,126.95. Insiders at Dynavax Technologies own 3.0% of the company. Learn More about insider trades at Dynavax Technologies.
Information on this page was last updated on 5/31/2024.

Andrew A. F. Hack Insider Trading History at Dynavax Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/8/2023	Sell	1,500,000	$14.39	$21,585,000.00	915,000
6/14/2023	Sell	500,000	$12.68	$6,340,000.00	2,415,000
12/6/2022	Sell	1,500,000	$11.60	$17,400,000.00	3,915,000
8/27/2021	Sell	2,000,000	$16.22	$32,440,000.00
8/9/2021	Sell	2,250,000	$10.80	$24,300,000.00
5/27/2020	Buy	1,000,000	$4.84	$4,840,000.00

Andrew A. F. Hack Buying and Selling Activity at Dynavax Technologies

Dynavax Technologies Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Today's Range

Now: $12.17

$11.75

$12.24

50 Day Range

MA: $11.45

$10.28

$13.66

2 Week Range

Now: $12.17

$9.74

$15.01

Volume

1,352,748 shs

Average Volume

3,092,731 shs

Market Capitalization

$1.60 billion

P/E Ratio

93.62

Dividend Yield

N/A

Beta

1.34

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad